Evidence map›Paper›PMID 31823219›Full record

ArticleJournal of gastrointestinal cancer2021

Anticancer Impacts of Terminalia catappa Extract on SW480 Colorectal Neoplasm Cell Line.

Dariush Shanehbandi, Habib Zarredar, Milad Asadi, Venus Zafari, Shiva Esmaeili, Ensiyeh Seyedrezazadeh, Zahra Soleimani, Hamed Sabagh Jadid, Shirin Eyvazi, Sara Feyziniya and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of gastrointestinal cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Bioactive compound from3 Biotech · 2022
    Article
  7. Article
  8. Article
  9. Pharmaceuticals (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Dariush ShanehbandiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Habib ZarredarTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran.
Milad AsadiImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Venus ZafariTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran.
Shiva EsmaeiliTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran.
Ensiyeh SeyedrezazadehTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran.
Zahra SoleimaniTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran.
Hamed Sabagh JadidTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran.
Shirin EyvaziTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran.
Sara FeyziniyaTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran.
Sedigheh Bamdad MoghadamDrug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Majid KhaliliTuberculosis and Lung Disease Research Center, Tabriz University of Medical Science, Daneshgah Street, Tabriz, Iran. Khalili876@gmail.com.
University of Tabriz · IRTabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeColorectal cancer (CRC) is one of the most lethal and prevalent cancers throughout the world. Despite the remarkable advance in the field, drug resistance still remains as an unresolved problem in cancer. Hence, finding effective compounds with minimal side effects to fight cancer is of central priority. Herbal products have been traditionally used to prevent and treat a variety of diseases.

methodsIn the present study, the antitumor effect of Terminalia catappa plant ethanolic extract (TCE) was assessed on SW480 CRC model cell line. In this regard, effects of TCE were evaluated on the proliferation, apoptosis, and migration of SW480 cells by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, Annexin V/PI flow cytometry, and scratch tests, respectively. Furthermore, changes in the expression of genes involved in these events including Bax, Bcl-2, Caspase 3, Caspase 8, Caspase 9, MMP-13, miR-21, and miR-34a were measured by quantitative real-time PCR (qRT-PCR).

resultsAccording to the MTT results, TCE reduced the proliferation of SW480 cells significantly. The flow cytometry test also revealed a notable rate of apoptosis induction after TCE treatment. An inhibitory effect on cell migration was also evident in scratch test. Expression patterns of the assessed genes also changed subsequent to TCE treatment.

conclusionThe results of this study indicated that T. catappa could be considered as a potential source of anticancer compounds and a candidate for further investigations.

Indexed as

ApoptosisCell Line, TumorCell MovementCell ProliferationColorectal NeoplasmsDrug Screening Assays, AntitumorGene Expression Regulation, NeoplasticHumansPlant ExtractsPlant LeavesTerminaliaPlant ExtractsApoptosisColorectal cancerMetastasisSW480Terminalia catappa

Identifiers

PMID31823219
OpenAlexW2996105169

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.